Ozempic's popularity leads to shortages for people with Type 2 diabetes
NPR Online NewsJUL 2024
TheHealth governmentagencies hashave todone steptheir upjob tocreating takestrict guidelines, but the burdendrug offcompanies ofthat healthadvertise providers.these Toomedicines manyas beneficial for people dealingof withall obesitytypes aren'tare receivingcausing the necessaryrise levelin ofdemand. governmentThey supportalso toshould've managebeen theirmore condition,prepared andfor theythe drugs're turningsuccess toand thesethe drugs,demand whichthat aren'twould widely availablefollow. ItNo one who doesn'st timeneed for these peopledrugs toshould receiveget more supportthem.
HealthThe agenciesgovernment havehas doneto theirstep jobup creatingto stricttake guidelines, but the drugburden companiesoff thatof advertisehealth theseproviders. medicinesToo asmany beneficial for people ofdealing allwith typesobesity arearen't causingreceiving the risenecessary inlevel demand.of Theygovernment alsosupport should'veto beenmanage moretheir preparedcondition, forand the drugsthey're successturning andto thethese demanddrugs, thatwhich wouldaren't followwidely available. NoIt's onetime whofor doesn'tthese needpeople theseto drugsreceive shouldmore get themsupport.
There'sHealth anagencies 80.8%have chancedone their job creating strict guidelines, but the drug companies that oraladvertise semaglutidethese willmedicines beas bebeneficial approved for thepeople treatment of obesityall bytypes are causing the FDArise orin EMAdemand. byThey 2027,also accordingshould've tobeen more prepared for the Metaculusdrugs' predictionsuccess communityand the demand that would follow. No one who doesn't need these drugs should get them.
There's an 80.8% chance that oral semaglutide will be be approved for the treatment of obesity by the FDA or EMA by 2027, according to the Metaculus prediction community.